Company appoints Rogerio Vivaldi, M.D. EVP and
chief global therapeutic operations officer, and John T. Greene,
EVP and chief financial officer
Biogen (NASDAQ: BIIB) today announced the addition of two
members to the executive management team of Bioverativ Inc.,
Biogen’s planned spin-off company focused on the discovery,
research, development and commercialization of treatments for
hemophilia and other blood disorders. Rogerio Vivaldi, M.D., will
serve as executive vice president and chief global therapeutic
operations officer of Bioverativ, and John T. Greene will serve as
executive vice president and chief financial officer of Bioverativ.
The spin-off of Bioverativ is on track to be completed in early
2017.
“Biogen is committed to positioning Bioverativ for success as it
prepares to carry forward our dedication to the hemophilia
community,” remarked George A. Scangos, Ph.D., chief executive
officer of Biogen. “Rogerio and John will be instrumental players
in that success, alongside the rest of the executive team.”
“Rogerio’s expertise in the industry and extensive knowledge of
the rare disease space will be critical as we work to deliver
transformative medicines to patients,” said John Cox, chief
executive officer of Bioverativ. “And, given John’s strong track
record of fiscal and operational management across all of the major
disciplines within finance, I am confident in his ability to lead
our global finance organization and be an excellent representative
for our shareholders.”
Dr. Vivaldi has more than 20 years of experience in delivering
orphan products to patients worldwide, most notably during his
tenure at Genzyme Corp., where he applied his medical and
professional expertise to lead the company's rare disease business
and earned a reputation as a passionate advocate for patients. Most
recently, he served as chief commercial officer at Spark
Therapeutics, a gene therapy company, and was co-founder, president
and CEO of Minerva Neurosciences.
He received his medical degree from Universidade do Rio de
Janeiro Medical School, and completed his residency in
endocrinology at Universidade do Estado do Rio de Janeiro and his
fellowship at Mount Sinai Hospital Center in New York in the
department of genetics. He received his MBA degree from COPPEAD,
Universidade Federal do Rio de Janeiro.
Dr. Vivaldi will be responsible for building and leading all
aspects of Bioverativ’s commercial organization, including
oversight of sales and marketing for the franchise’s lead products,
ELOCTATE® and ALPROLIX®, extended half-life therapies for the
treatment of hemophilia A and hemophilia B, respectively. He will
report to Bioverativ CEO John Cox.
“Bioverativ is a unique opportunity to join a new company with a
strong commercial business, growing pipeline and an experienced
team dedicated to delivering results for patients, providers and
caregivers,” said Dr. Vivaldi. “I am passionate about improving
lives through innovative therapies and ardent patient advocacy, and
believe Bioverativ shares this vision.”
Mr. Greene joins Bioverativ from Willis Group, plc, where he
served as chief financial officer, enhancing business analytics and
company performance while helping to execute on an ambitious merger
and acquisition program. Previously, he was chief financial officer
for HSBC Holdings, earning positions of increasing responsibility
over eight years with the company, including Chief Financial
Officer for the Global Retail Bank and Wealth Management business.
Earlier in his career, Mr. Greene spent 12 years in various roles
at General Electric. He earned his undergraduate degree from the
State University of New York and an MBA from Northwestern
University’s Kellogg School of Management.
“I am excited about the opportunity to apply my experience to a
field that makes a meaningful difference in the lives of those it
serves,” said Mr. Greene. “I look forward to working with the
Bioverativ leadership team to create a leading organization that I
believe is well-positioned for growth based on world-class science
and a focus on addressing serious unmet needs in the blood
disorders community.”
Mr. Greene will be responsible for all financial and fiscal
management of Bioverativ’s operations, with oversight for the
company’s finance, information technology and technical operations
functions. He will also work closely with business development, and
research and development to grow the business. He will also report
to Mr. Cox.
About BiogenThrough cutting-edge science and medicine,
Biogen discovers, develops and delivers worldwide innovative
therapies for people living with serious neurological, autoimmune
and rare diseases. Founded in 1978, Biogen is one of the world’s
oldest independent biotechnology companies and patients worldwide
benefit from its leading multiple sclerosis and innovative
hemophilia therapies. For more information, please visit
www.biogen.com. Follow us on Twitter.
Safe HarborThis press release contains forward-looking
statements, including, without limitation, statements relating to
the proposed spin-off of Biogen’s hemophilia business, such as the
completion and timing of the proposed spin-off, the expected
appointments to Bioverativ’s management team, and business
prospects of Bioverativ. These forward-looking statements may be
accompanied by such words as “anticipate,” “believe,” “could,”
“estimate,” “expect,” “forecast,” “intend,” “may,” “plan,”
“potential,” “project,” “target,” “will” and other words and terms
of similar meaning. You should not place undue reliance on these
statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including, without limitation, risks that the
proposed spin-off will be completed in a timely manner or at all;
risks of failure to satisfy any conditions to the proposed
spin-off; risks of failure of the proposed spin-off to qualify as a
tax-free transaction for U.S. federal income tax purposes;
uncertainty of whether the anticipated benefits of the spin-off can
be achieved; risks of unexpected costs or delays; and risks and
uncertainties associated with the development and commercialization
of products and product candidates that may impact or alter
anticipated business plans, strategies, objectives, and capital
structure. The foregoing sets forth many, but not all, of the
factors that could cause actual results to differ from our
expectations in any forward-looking statement. Investors should
consider this cautionary statement, as well as the risk factors
identified in our most recent annual or quarterly report and in
other reports we have filed with the U.S. Securities and Exchange
Commission. These statements are based on our current beliefs and
expectations and speak only as of the date of this press release.
We do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of new information,
future developments or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161115005927/en/
BiogenMEDIA CONTACT:Tracy Vineis, +1
781-464-3260public.affairs@biogen.comorINVESTOR CONTACT:Susan
Altschuller, +1 781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2023 to Mar 2024